Israel Reopens Anti-Dumping Investigation Into Canadian Cannabis Imports

Investigation Targets Canadian Medical Cannabis Exports

The Israeli Trade Remedies Authority (TRA) will examine whether Canadian licensed producers sold medical cannabis flower below production cost in the Israeli market between January 2024 and June 2026. The investigation follows a petition filed by Israel's domestic cannabis growers' association, which represents approximately 40 licensed cultivation facilities operating under the Israeli Medical Cannabis Agency (IMCA).

Canadian exports to Israel totaled an estimated 18,000 kilograms of dried flower in 2025, according to Health Canada export data. Israeli petitioners argue that Canadian LPs—facing oversupply and depressed domestic prices—offloaded inventory into Israel at prices as low as $1.20 USD per gram wholesale. That undercuts Israeli producers' average cost of $2.10 per gram.

Case History and 2025 Suspension

The TRA first opened the investigation in March 2025 but suspended proceedings in November 2025 after Canadian exporters agreed to voluntary price undertakings. Those undertakings committed Canadian suppliers to minimum export prices of $1.85 USD per gram FOB.

The TRA's August 9 notice states that "new evidence of sustained below-cost sales" emerged in the first half of 2026, prompting the reopening. Israeli customs data reviewed by the TRA reportedly shows shipments invoiced at $1.30-$1.50 per gram during Q1 and Q2 2026. Below the agreed floor.

Potential Tariff Range and Timeline

If the TRA finds dumping and material injury, Israel could impose anti-dumping duties ranging from 25% to 40% on Canadian cannabis imports. The investigation timeline calls for:

• Preliminary findings by November 2026
• Public comment period through December 2026
• Final determination by February 2027
• Tariffs effective 30 days after final ruling

Provisional duties could be imposed as early as December 2026 if the TRA's preliminary report supports the dumping allegation.

Impact on Canadian Licensed Producers

Israel represents the second-largest export market for Canadian medical cannabis, behind only Germany. Canadian LPs shipped approximately $22 million CAD worth of dried flower and oils to Israel in 2025, according to Health Canada's quarterly export reports.

Tariffs in the 30%+ range would effectively close the Israeli market to most Canadian suppliers, whose margins on export sales already average less than 15%. Major Canadian exporters to Israel include Tilray Medical, Aurora Cannabis, and Organigram, though none have publicly commented on the reopened investigation.

Israeli Domestic Industry Claims

Israeli cultivators argue that Canadian dumping has driven wholesale flower prices down 38% since early 2024, forcing facility closures and layoffs. The domestic growers' petition cites three licensed producers that ceased operations in 2025, eliminating approximately 200 jobs.

Israeli cultivation costs remain structurally higher than Canada's due to water scarcity, energy costs, and smaller-scale operations—factors that the TRA will weigh against claims of competitive disadvantage versus genuine dumping.

Israel's medical cannabis program serves roughly 130,000 registered patients. Domestic production supplies an estimated 65% of demand. Imports—primarily from Canada, Portugal, and the Netherlands—fill the gap.

Trade Law Framework and WTO Compliance

Israel's anti-dumping procedures follow World Trade Organization (WTO) guidelines under the Agreement on Implementation of Article VI of GATT 1994. The TRA must demonstrate both below-cost sales and a causal link between those sales and injury to the domestic industry.

Canadian exporters may challenge the findings through the TRA's administrative review process or escalate to WTO dispute settlement if tariffs are imposed. Canada hasn't yet filed a formal response to the reopened investigation.

What to Watch

The preliminary report in November will signal whether provisional duties are likely. Canadian LPs with significant Israeli exposure may seek renewed price undertakings to avoid tariffs, though the TRA's willingness to accept a second round of commitments is uncertain after the alleged 2026 breaches.

For full background on this story, see the CannIntel topic hub on Israel-Canada Cannabis Trade. The outcome will set a precedent for how cannabis-exporting nations handle surplus inventory without triggering trade remedies in smaller import markets.